• Combining Opdivo with BMS-986205 Shows Promise in Advanced Cervical, Bladder Cancers
  • Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma
  • Cancer Immunotherapy IMCgp100 Shows Early Positive Results in Advanced Uveal Melanoma
  • Early Results Suggest Opdivo Combo May Help People with Advanced Pancreatic Cancer
  • Boehringer Ingelheim, Sarah Cannon Research Institute to Study New Combo Therapy
  • FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN
  • FDA OKs Batu Biologics’ ValloVax for Clinical Investigation in Certain Solid Tumors
  • Super T-cells that Launch Dual Attack on Cancer Cells Enter Clinical Evaluation
  • CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies
  • UniQuest Partners with Merck Sharp & Dohme to Develop Immuno-Oncology Therapies in Australia
  • Opdivo Moves a Step Closer to Being Expanded to Another Melanoma Patient Population
  • Prof. Laurence Zitvogel’s Work Recognized with First ESMO Award for Immuno-Oncology